|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC CancerBase No. 11 (Internet). International Agency
for Research on Cancer; Lyon, France: 2013, http://globocan.iarc.fr.
Accessed April 01, 2014.
|
|
2
|
Ling V: Multidrug resistance: Molecular
mechanisms and clinical relevance. Cancer Chemother Pharmacol.
40(Suppl): S3–S8. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Naito S, Yokomizo A and Koga H: Mechanisms
of drug resistance in chemotherapy for urogenital carcinoma. Int J
Urol. 6:427–439. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pérez-Tomás R: Multidrug resistance:
Retrospect and prospects in anti-cancer drug treatment. Curr Med
Chem. 13:1859–1876. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanaka H, Kono E, Tran CP, Miyazaki H,
Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, et
al: Monoclonal antibody targeting of N-cadherin inhibits prostate
cancer growth, metastasis and castration resistance. Nat Med.
16:1414–1420. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Soothill JS, Ward R and Girling AJ: The
IC50: An exactly defined measure of antibiotic sensitivity. J
Antimicrob Chemother. 29:137–139. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang Y, Toy W, Choong LY, Hou P, Ashktorab
H, Smoot DT, Yeoh KG and Lim YP: Discovery of SLC3A2 cell membrane
protein as a potential gastric cancer biomarker: Implications in
molecular imaging. J Proteome Res. 11:5736–5747. 2012.PubMed/NCBI
|
|
8
|
Finney DJ: Probit analysis; a statistical
treatment of the sigmoid response curve. 1st edition. Macmillan;
Oxford: pp. 2561947
|
|
9
|
Tong SW, Yang YX, Hu HD, An X, Ye F, Hu P,
Ren H, Li SL and Zhang DZ: Proteomic investigation of
5-fluorouracil resistance in a human hepatocellular carcinoma cell
line. J Cell Biochem. 113:1671–1680. 2012.
|
|
10
|
Yang Y, Lim SK, Choong LY, Lee H, Chen Y,
Chong PK, Ashktorab H, Wang TT, Salto-Tellez M, Yeoh KG, et al:
Cathepsin S mediates gastric cancer cell migration and invasion via
a putative network of metastasis-associated proteins. J Proteome
Res. 9:4767–4778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Haraguchi N, Inoue H, Tanaka F, Mimori K,
Utsunomiya T, Sasaki A and Mori M: Cancer stem cells in human
gastrointestinal cancers. Hum Cell. 19:24–29. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lou Y, Li R, Xiong L, Gu A, Shi C, Chu T,
Zhang X, Gu P, Zhong H, Wen S, et al: NAD(P)H: quinone
oxidoreductase 1 (NQO1) C609T polymorphism and lung cancer risk: a
meta-analysis. Tumour Biol. 34:3967–3979. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mikami K, Tabata C, Tabata R, Nogi Y,
Terada T, Honda M, Kamiya H, Nishizaki T and Nakano T: Clinical
significance of serum angiopoietin-1 in malignant peritoneal
mesothelioma. Cancer Invest. 31:511–515. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rhodes SL, Buchanan DD, Ahmed I, Taylor
KD, Loriot MA, Sinsheimer JS, Bronstein JM, Elbaz A, Mellick GD,
Rotter JI, et al: Pooled analysis of iron-related genes in
Parkinson's disease: Association with transferrin. Neurobiol Dis.
62:172–178. 2014. View Article : Google Scholar :
|
|
15
|
Pavlou MP and Diamandis EP: The cancer
cell secretome: A good source for discovering biomarkers? J
Proteomics. 73:1896–1906. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Soltermann A, Ossola R, Kilgus-Hawelski S,
von Eckardstein A, Suter T, Aebersold R and Moch H: N-glycoprotein
profiling of lung adenocarcinoma pleural effusions by shotgun
proteomics. Cancer. 114:124–133. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang CL, Wang CI, Liao PC, Chen CD, Liang
Y, Chuang WY, Tsai YH, Chen HC, Chang YS, Yu JS, et al: Discovery
of retinoblastoma-associated binding protein 46 as a novel
prognostic marker for distant metastasis in nonsmall cell lung
cancer by combined analysis of cancer cell secretome and pleural
effusion proteome. J Proteome Res. 8:4428–4440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pilch B and Mann M: Large-scale and
high-confidence proteomic analysis of human seminal plasma. Genome
Biol. 7:R402006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hsu CW, Yu JS, Peng PH, Liu SC, Chang YS,
Chang KP and Wu CC: Secretome profiling of primary cells reveals
that THBS2 is a salivary biomarker of oral cavity squamous cell
carcinoma. J Proteome Res. 13:4796–4807. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gloghini A, Volpi CC, Caccia D, Gualeni
AV, Cilia AM, Carbone A and Bongarzone I: Primary effusion
lymphoma: Secretome analysis reveals novel candidate biomarkers
with potential pathogenetic significance. Am J Pathol. 184:618–630.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mathews ST, Chellam N, Srinivas PR,
Cintron VJ, Leon MA, Goustin AS and Grunberger G: α2-HSG, a
specific inhibitor of insulin receptor autophosphorylation,
interacts with the insulin receptor. Mol Cell Endocrinol.
164:87–98. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pal D, Dasgupta S, Kundu R, Maitra S, Das
G, Mukhopadhyay S, Ray S, Majumdar SS and Bhattacharya S: Fetuin-A
acts as an endogenous ligand of TLR4 to promote lipid-induced
insulin resistance. Nat Med. 18:1279–1285. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao ZW, Lin CG, Wu LZ, Luo YK, Fan L,
Dong XF and Zheng H: Serum fetuin-A levels are associated with the
presence and severity of coronary artery disease in patients with
type 2 diabetes. Biomarkers. 18:160–164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kaushik SV, Plaisance EP, Kim T, Huang EY,
Mahurin AJ, Grandjean PW and Mathews ST: Extended-release niacin
decreases serum fetuin-A concentrations in individuals with
metabolic syndrome. Diabetes Metab Res Rev. 25:427–434. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu Y, Xu M, Bi Y, Song A, Huang Y, Liu Y,
Wu Y, Chen Y, Wang W, Li X, et al: Serum fetuin-A is correlated
with metabolic syndrome in middle-aged and elderly Chinese.
Atherosclerosis. 216:180–186. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Haukeland JW, Dahl TB, Yndestad A,
Gladhaug IP, Løberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET,
Johansen OE, et al: Fetuin A in nonalcoholic fatty liver disease:
In vivo and in vitro studies. Eur J Endocrinol. 166:503–510. 2012.
View Article : Google Scholar
|
|
27
|
Yilmaz Y, Yonal O, Kurt R, Ari F, Oral AY,
Celikel CA, Korkmaz S, Ulukaya E, Ozdogan O, Imeryuz N, et al:
Serum fetuin A/α2HS-glycoprotein levels in patients with
non-alcoholic fatty liver disease: Relation with liver fibrosis.
Ann Clin Biochem. 47:549–553. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guillory B, Sakwe AM, Saria M, Thompson P,
Adhiambo C, Koumangoye R, Ballard B, Binhazim A, Cone C,
Jahanen-Dechent W, et al: Lack of fetuin-A (α2-HS-glycoprotein)
reduces mammary tumor incidence and prolongs tumor latency via the
transforming growth factor-β signaling pathway in a mouse model of
breast cancer. Am J Pathol. 177:2635–2644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Swallow CJ, Partridge EA, Macmillan JC,
Tajirian T, DiGuglielmo GM, Hay K, Szweras M, Jahnen-Dechent W,
Wrana JL, Redston M, et al: α2HS-glycoprotein, an antagonist of
transforming growth factor β in vivo. Inhibits intestinal tumor
progression. Cancer Res. 64:6402–6409. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thompson PD, Sakwe A, Koumangoye R,
Yarbrough WG, Ochieng J and Marshall DR: α-2 heremans schmid
glycoprotein (AHSG) modulates signaling pathways in head and neck
squamous cell carcinoma cell line SQ20B. Exp Cell Res. 321:123–132.
2014. View Article : Google Scholar :
|
|
31
|
Bach F, Uddin FJ and Burke D:
Angiopoietins in malignancy. Eur J Surg Oncol. 33:7–15. 2007.
View Article : Google Scholar
|
|
32
|
Fagiani E and Christofori G: Angiopoietins
in angiogenesis. Cancer Lett. 328:18–26. 2013. View Article : Google Scholar
|
|
33
|
Martin V, Xu J, Pabbisetty SK, Alonso MM,
Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, et al:
Tie2-mediated multidrug resistance in malignant gliomas is
associated with upregulation of ABC transporters. Oncogene.
28:2358–2363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mazzieri R, Pucci F, Moi D, Zonari E,
Ranghetti A, Berti A, Politi LS, Gentner B, Brown JL, Naldini L, et
al: Targeting the ANG2/TIE2 axis inhibits tumor growth and
metastasis by impairing angiogenesis and disabling rebounds of
proangiogenic myeloid cells. Cancer Cell. 19:512–526. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tait CR and Jones PF: Angiopoietins in
tumours: The angiogenic switch. J Pathol. 204:1–10. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tong Z, Kunnumakkara AB, Wang H, Matsuo Y,
Diagaradjane P, Harikumar KB, Ramachandran V, Sung B, Chakraborty
A, Bresalier RS, et al: Neutrophil gelatinase-associated lipocalin:
A novel suppressor of invasion and angiogenesis in pancreatic
cancer. Cancer Res. 68:6100–6108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang J, McNeish B, Butterfield C and Moses
MA: Lipocalin 2 is a novel regulator of angiogenesis in human
breast cancer. FASEB J. 27:45–50. 2013. View Article : Google Scholar :
|
|
38
|
Iannetti A, Pacifico F, Acquaviva R,
Lavorgna A, Crescenzi E, Vascotto C, Tell G, Salzano AM, Scaloni A,
Vuttariello E, et al: The neutrophil gelatinase-associated
lipocalin (NGAL), a NF-κB-regulated gene, is a survival factor for
thyroid neoplastic cells. Proc Natl Acad Sci USA. 105:14058–14063.
2008. View Article : Google Scholar
|
|
39
|
Suk K: Proteomic analysis of glioma
chemoresistance. Curr Neuropharmacol. 10:72–79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng LT, Lee S, Yin GN, Mori K and Suk K:
Down-regulation of lipocalin 2 contributes to chemoresistance in
glioblastoma cells. J Neurochem. 111:1238–1251. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Squarize CH, Castilho RM, Abrahao AC,
Molinolo A, Lingen MW and Gutkind JS: PTEN deficiency contributes
to the development and progression of head and neck cancer.
Neoplasia. 15:461–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
